The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target

MT NewswiresDec 19 20:40 · Ratings

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21

Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15 12:17

This week's Hong Kong stock bull | The "first domestic makeup stock" in Hong Kong! Mao Ge Ping soared over 86% in its first week of listing; Consumer encouragement policies are expected to continue to strengthen, and Lao Pu Gold has increased by over 20%.

This week, the Hang Seng Index increased by 0.53%, closing at 19,971.24 points; during the same period, the Hang Seng TECH Index rose by 0.33%, closing at 4,479.6 points; the Hang Seng China Enterprises Index increased by 0.7%, closing at 7,186.59 points.

Futu NewsDec 14 11:52

HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla

MT NewswiresDec 13 12:23